Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker azd1305 versus dofetilide in dogs with remodeled hearts

Circulation: Arrhythmia and Electrophysiology

Volumn 5, Issue 1, 2012, Pages 201-209

  Johnson, Daniel M ^a   De Jong, Monique M J ^a   Crijns, Harry J G M ^a   Carlsson, Leif G ^b   Volders, Paul G A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiarrhythmic drugs; Ion channels; Remodeling; Torsade de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; AZD 1305; DOFETILIDE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLETE HEART BLOCK; CONTROLLED STUDY; DOG; DRUG STRUCTURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RR INTERVAL; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

ANIMALS; ATRIOVENTRICULAR BLOCK; AZABICYCLO COMPOUNDS; CARBAMATES; DISEASE MODELS, ANIMAL; DOGS; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HEART RATE; MALE; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; SULFONAMIDES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84863378058     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.111.963025     Document Type: Article

References (35)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98:946-950
2. Guo AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375 (Pubitemid 32424106)
3. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, Ezrin AM, Beatch GN. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238
4. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518-1525 (Pubitemid 351440640)
5. Dobrev D, Hamad B, Kirkpatrick P. Vernakalant. Nat Rev Drug Discov 2010;9:915-916
6. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605
7. Carlsson L, Andersson B, Linhardt G, Löfberg L. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine- sensitized rabbit in vivo. J Cardiovasc Pharmacol. 2009;54: 82-89
8. Andersson B, Abi-Gerges N, Carlsson L. The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. Europace. 2010;12: 1003-1010
9. Burashnikov A, Zygmunt AC, Di Diego JM, Linhardt G, Carlsson L, Antzelevitch C. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol. 2010;56:80-90
10. Sicouri S, Carlsson L, Antzelevitch C. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. J Pharmacol Exp Ther. 2010;334:255-259
11. Toivonen L, Raatikainen P, Walfridsson H, Englund A, Hegbom F, Anfinsen OG, Gjesdal K, Pehrson S, Johansson S, Frison L, Berggren AR, Edvardsson N. A randomized, invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter. J Cardiovasc Pharmacol. 2010;56: 300-308
12. Rónaszéki A, Alings M, Egstrup K, Gaciong Z, Hranai M, Király C, Sereg M, Figatowski W, Bondarov P, Johansson S, Frison L, Edvardsson N, Berggren A. Pharmacological cardioversion of atrial fibrillation-a double-blind, randomized, placebo-controlled, multicentre, doseescalation study of AZD1305 given intravenously. Europace. 2011;13: 1148-1156
13. Volders PG, Sipido KR, Vos MA, Kulcsár A, Verduyn SC, Wellens HJ. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation. 1998;98:1136-1147 (Pubitemid 28420706)
14. Volders PG, Sipido KR, Vos MA, Spätjens RL, Leunissen JD, Carmeliet E, Wellens HJ. Downregulation of delayed rectifier K+ currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation. 1999;100:2455-2461
15. Stengl M, Ramakers C, Donker DW, Nabar A, Rybin AV, Spätjens RL, van der Nagel T, Wodzig WK, Sipido KR, Antoons G, Moorman AF, Vos MA, Volders PG. Temporal patterns of electrical remodeling in canine ventricular hypertrophy: Focus on IKs downregulation and blunted betaadrenergic activation. Cardiovasc Res. 2006;72:90-100 (Pubitemid 44429905)
16. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods. 1989;22:207-217 (Pubitemid 19275446)
17. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol 2005;15:1444-1450
18. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res. 1993;27:2186-2193 (Pubitemid 24034733)
19. Carlsson L, Drews L, Duker G, Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther. 1993;267:1076-1080 (Pubitemid 24068667)
20. Antoons G, Oros A, Beekman JD, Engelen MA, Houtman MJ, Belardinelli L, Stengl M, Vos MA. Late Na+ current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010;55:801-809
21. Oros A, Houtman MJ, Neco P, Gomez AM, Rajamani S, Oosterhoff P, Attevelt NJ, Beekman JD, van der Heyden MA, Ver Donck L, Belardinelli L, Richard S, Antoons G, Vos MA; CONTICA investigators. Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. Br J Pharmacol. 2010;161:162-175
22. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, Volders PG, Vos MA. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation. 2004;110:2453-2459 (Pubitemid 39407353)
23. Thomsen MB, Beekman JD, Attevelt NJ, Takahara A, Sugiyama A, Chiba K, Vos MA. No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol. 2006;149:1039-1048 (Pubitemid 44950807)
24. Lengyel C, Varró A, Tábori K, Papp JG, Baczkó I. Combined pharmacological block of IKr and IKs increases short-term QT interval variability and provokes torsades de pointes. Br J Pharmacol. 2007;151:941-951 (Pubitemid 47195521)
25. Jacobson I, Carlsson L, Duker G. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. J Pharmacol Toxicol Methods. 2011;63:40-46
26. Hinterseer M, Thomsen MB, Beckmann BM, Pfeufer A, Schimpf R, Wichmann HE, Steinbeck G, Vos MA, Kaab S. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: A case control pilot study. Eur Heart J. 2008;29:185-190
27. Hinterseer M, Beckmann BM, Thomsen MB, Pfeufer A, Dalla Pozza R, Loeff M, Netz H, Steinbeck G, Vos MA, Kääb S. Relation of increased short-term variability of QT interval to congenital long-QT syndrome. Am J Cardiol. 2009;103:1244-1248
28. Hinterseer M, Beckmann BM, Thomsen MB, Pfeufer A, Ulbrich M, Sinner MF, Perz S, Wichmann HE, Lengyel C, Schimpf R, Maier SK, Varró A, Vos MA, Steinbeck G, Kääb S. Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and proarrhythmia in patients with nonischemic heart failure. Am J Cardiol 2010;106:216-220
29. Crijns HJ, Van Gelder IC, Walfridsson H, Kulakowski P, Rónaszéki A, Dedek V, Malm A, Almgren O. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006;3:1321-1331 (Pubitemid 44636926)
30. Geller JC, Egstrup K, Kulakowski P, Rosenqvist M, Jansson MA, Berggren A, Edvardsson N, Sager P, Crijns HJ. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol. 2009;49:312-322
31. Turina M, Baboti I, Bussmann WD, Krayenbühl HP. Haemodynamics of acute and chronic atrioventricular block in dogs. Cardiovasc Res. 1969; 3:209-217
32. Neuberger HR, Schotten U, Verheule S, Eijsbouts S, Blaauw Y, van Hunnik A, Allessie M. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation. 2005;111: 30-37 (Pubitemid 40070840)
33. Blaauw Y, Schotten U, van HA, Neuberger HR, Allessie MA. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res. 2007;75: 89-98 (Pubitemid 46873519)
34. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999;100:87-95 (Pubitemid 29297945)
35. Li D, Bénardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000;102:104-112. (Pubitemid 30430560)